1. Anti-infection
    Metabolic Enzyme/Protease
  2. HIV
    HIV Protease

Atazanavir (Synonyms: BMS 232632; BMS-232632; BMS232632)

Cat. No.: HY-17367
Handling Instructions

Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor.

For research use only. We do not sell to patients.
Atazanavir Chemical Structure

Atazanavir Chemical Structure

CAS No. : 198904-31-3

Size Price Stock Quantity
10 mg $60 Backordered
50 mg $120 Backordered
100 mg $200 Backordered

* Please select Quantity before adding items.

Other Forms of Atazanavir:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor. IC50 value: Target: HIV-1 protease inhibitor Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1]. After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2]. Clinical indications: HIV-1 infection Toxicity: torsades de pointes

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01837719 Bristol-Myers Squibb Human Immunodeficiency Virus Type 1 (HIV-1) April 2013 Phase 1
NCT00916448 Radboud University Endotoxemia|Inflammation|Multi Organ Dysfunction Syndrome|Sepsis May 2009
NCT00940771 Phoenix Children's Hospital|Bristol-Myers Squibb Pediatric HIV|HIV Infections April 2009 Phase 4
NCT01404572 Bristol-Myers Squibb HIV August 2011 Phase 1
NCT01599364 Catholic University of the Sacred Heart Human Immunodeficiency Virus April 2014 Phase 4
NCT02034838 Ottawa Hospital Research Institute|Bristol-Myers Squibb HIV Infection January 2014 Phase 1
NCT03019783 Brigham and Women's Hospital HIV December 2011 Phase 2|Phase 3
NCT00874523 Kirby Institute HIV Infection July 2009 Phase 3
NCT00225017 Northwestern University|Bristol-Myers Squibb HIV Infection|Hyperlipidemia June 2005 Phase 3
NCT00833482 Bristol-Myers Squibb Human Immunodeficiency Virus Type 1 (HIV-1)|HIV Infections September 2009 Phase 1
NCT01759875 University of California, San Francisco Healthy January 2013 Phase 1
NCT00357721 Bristol-Myers Squibb HIV Infections|Protease Inhibitor June 2006 Phase 1
NCT01335698 Bristol-Myers Squibb HIV May 27, 2011 Phase 3
NCT01232127 Bristol-Myers Squibb HIV February 2011 Phase 4
NCT01099579 Bristol-Myers Squibb HIV Infections October 13, 2010 Phase 3
NCT01691794 Bristol-Myers Squibb HIV, Pediatric November 2012 Phase 4
NCT00035932 Bristol-Myers Squibb HIV Infections November 2001 Phase 3
NCT00357604 Bristol-Myers Squibb HIV Infections July 2006 Phase 1
NCT00357188 Bristol-Myers Squibb HIV Infections|Protease Inhibitor July 2006 Phase 1
NCT01928407 Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba HIV-1 Infection|Immunosuppression-related Infectious Disease March 2011 Phase 4
NCT02102048 University of Roma La Sapienza HIV January 2009
NCT00768989 Bristol-Myers Squibb|Merck Sharp & Dohme Corp. HIV November 2008 Phase 2
NCT00413153 Massachusetts General Hospital|Bristol-Myers Squibb HIV Infections May 2006
NCT00326716 Bristol-Myers Squibb HIV Infection June 2006 Phase 1
NCT02566707 Radboud University HIV-1 Infection August 2015 Phase 2
NCT00224445 Gilead Sciences HIV Infections September 2005 Phase 4
NCT00160329 Stanford University|Bristol-Myers Squibb Hyperlipidemia|HIV Infections January 2004 Phase 3
NCT00337467 Bristol-Myers Squibb Human Immunodeficiency Virus (HIV) Infections June 2006 Phase 3
NCT00280969 International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan HIV Infection September 2005 Phase 3
NCT00696722 Radboud University|Dutch Diabetes Research Foundation Type 2 Diabetes Mellitus Related Endothelial Dysfunction June 2008 Phase 2
NCT00362726 Bristol-Myers Squibb HIV Infections September 2006 Phase 1
NCT01351740 University of British Columbia HIV Infection July 2011 Phase 4
NCT00355719 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital San Jaime de Calella HIV Infections January 2007 Phase 4
NCT01511809 Ospedale San Raffaele|Bristol-Myers Squibb HIV-1 Infection September 2010 Phase 3
NCT02589158 St Stephens Aids Trust|Bristol-Myers Squibb HIV November 2015 Phase 1
NCT01194856 The Cleveland Clinic|National Institute of Allergy and Infectious Diseases (NIAID)|Case Western Reserve University|Bristol-Myers Squibb HIV Infection|Mitochondrial Dysfunction October 2010 Phase 4
NCT01073761 St Stephens Aids Trust HIV|HIV Infections April 2010 Phase 1
NCT01368783 Asan Medical Center|Bristol-Myers Squibb Atazanavir June 2011 Phase 1
NCT00420355 University of Oklahoma|Abbott HIV Infection April 2007 Phase 4
NCT00447070 Foundation for Cardiovascular Research, Zurich|Bristol-Myers Squibb HIV Infections|Dyslipidemia August 2004 Phase 4
NCT02473328 Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|INSERM UMR S 1136 HIV-1 Infection June 2015 Phase 2
NCT02542852 Castagna Antonella|Bristol-Myers Squibb|ViiV Healthcare|Ospedale San Raffaele HIV-1 Infection September 2015 Phase 2
NCT00312754 Bristol-Myers Squibb HIV Infections June 2005 Phase 4
NCT01818856 Hospitales Universitarios Virgen del Rocío|Bristol-Myers Squibb Hepatitis C, Chronic|HIV Infection December 2012 Phase 1
NCT00135356 Bristol-Myers Squibb HIV-Associated Lipodystrophy Syndrome July 2005 Phase 4
NCT00013897 Bristol-Myers Squibb HIV Infections February 2001 Phase 3
NCT01255371 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|European and Developing Countries Clinical Trials Partnership (EDCTP)|Ludwig-Maximilians - University of Munich|Institute of Tropical Medicine, Belgium|Institut de Recherche pour le Developpement, France|Swiss National Science Foundation|University of Limpopo|NIMR-Mbeya Medical Research Program (MMRP)/ Mbeya Referral Hospital, Tanzania HIV March 2012 Phase 3
NCT01389310 Bristol-Myers Squibb|PENTA Foundation HIV Infection July 2011
NCT00393328 Bristol-Myers Squibb HIV Infections November 2006 Phase 1
NCT00751153 Peter J. Ruane, M.D., Inc. HIV Infections March 2008 Phase 4
NCT01332227 Bristol-Myers Squibb HIV, Combination Therapy October 2011 Phase 4
NCT00762892 The University of Texas Health Science Center, Houston|Merck Sharp & Dohme Corp. HIV Infections January 2009 Phase 4
NCT00004584 Bristol-Myers Squibb HIV Infections December 1999 Phase 2
NCT00883935 GlaxoSmithKline|Shionogi Healthy Volunteer April 2009 Phase 1
NCT01940198 Holdsworth House Medical Practice|Bristol-Myers Squibb HIV April 2010
NCT01102972 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus April 2010 Phase 4
NCT00885482 Catholic University of the Sacred Heart HIV Infections May 2009 Phase 4
NCT00162149 Bristol-Myers Squibb HIV Infections October 2005 Phase 1
NCT00207142 Bristol-Myers Squibb HIV Infections November 2005 Phase 4
NCT00827112 ViiV Healthcare|Pfizer Human Immunodeficiency Virus-1 March 2009 Phase 2
NCT00002240 Bristol-Myers Squibb HIV Infections March 1999 Phase 2
NCT00084253 Bristol-Myers Squibb HIV Infections June 2004 Phase 4
NCT02532673 Bristol-Myers Squibb HIV/AIDS August 2014
NCT00272779 Bristol-Myers Squibb HIV Infections November 2005 Phase 3
NCT00943540 Radboud University HIV Infection|HIV Infections July 2009 Phase 2
NCT00528060 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences HIV Infections January 2008 Phase 2
NCT02442700 Ramathibodi Hospital HIV|Dyslipidemia May 2014 Phase 4
NCT02565888 Radboud University Hepatitis C|HIV November 2015 Phase 1
NCT00082394 GlaxoSmithKline Infection, Human Immunodeficiency Virus I|HIV Infection April 26, 2004 Phase 4
NCT02307656 Bristol-Myers Squibb HIV in Adults November 21, 2014 Phase 1
NCT00411957 The HIV Netherlands Australia Thailand Research Collaboration|Bristol-Myers Squibb HIV Infections January 2007 Phase 1|Phase 2
NCT00384904 Bristol-Myers Squibb HIV Infections December 2006 Phase 4
NCT00389402 International Antiviral Therapy Evaluation Center|Hoffmann-La Roche|Gilead Sciences HIV Infections July 2006 Phase 4
NCT01003990 Bristol-Myers Squibb HIV October 2002 Phase 3
NCT00931801 Community Research Initiative of New England|Bristol-Myers Squibb|Merck Sharp & Dohme Corp. HIV December 2009 Phase 4
NCT01475227 St Stephens Aids Trust HIV Infection December 2011 Phase 4
NCT00242216 The University of Texas Health Science Center, Houston HIV Infections May 2004 Phase 4
NCT00067782 Bristol-Myers Squibb HIV Infections December 2002 Phase 3
NCT00720590 National Heart, Lung, and Blood Institute (NHLBI) Endothelial Dysfunction November 2003
NCT01450605 Bristol-Myers Squibb HIV-1 December 2011
NCT01902186 Giovanni Di Perri|University of Turin, Italy|University of Milan HIV Infection|Osteopenia September 2014 Phase 4
NCT00646776 Bristol-Myers Squibb Antivirals/HIV April 2008 Phase 1
NCT00389207 Boehringer Ingelheim HIV Infections October 2006 Phase 3
NCT00757783 Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV October 2008 Phase 4
NCT02652793 David Garcia Cinca|Jose Luis Blanco - Fundació Clínic per a la Recerca Biomèdica|Hospital Clinic of Barcelona Human Immunodeficiency Virus July 2015
NCT00440947 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus I|HIV Infection March 2007 Phase 3
NCT00135343 Bristol-Myers Squibb HIV Infections April 2004 Phase 3
NCT00028067 Bristol-Myers Squibb HIV Infections August 2001 Phase 3
NCT00122577 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences HIV Infections March 2002 Phase 2
NCT00084019 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections July 2004
NCT01592305 Hoffmann-La Roche Healthy Volunteer May 2012 Phase 1
NCT00120393 Bristol-Myers Squibb HIV Infections January 2004 Phase 3
NCT01421355 Brigham and Women's Hospital|National Institutes of Health (NIH) Type 1 Diabetes Mellitus May 2012 Phase 1
NCT00552240 Boehringer Ingelheim HIV Infections September 2007 Phase 4
NCT00426296 Clinical Alliance for Research & Education - Infectious Diseases, LLC.|GlaxoSmithKline HIV Infections|Lipodystrophy August 2006 Phase 4
NCT02253836 Boehringer Ingelheim Healthy January 2005 Phase 1
NCT01180075 University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID) Human Immunodeficiency Virus May 2010
NCT00046345 Bristol-Myers Squibb HIV Infections May 2002
NCT00192608 Kirby Institute|Hoffmann-La Roche HIV Infections November 2004
NCT01307488 Fundacion SEIMC-GESIDA|Bristol-Myers Squibb HIV Infection September 2011 Phase 4
NCT00544128 International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan HIV Infections October 2007 Phase 4
NCT00357240 Bristol-Myers Squibb HIV Infections June 2006 Phase 1
NCT01591850 Hoffmann-La Roche Healthy Volunteer September 2011 Phase 1
NCT01458769 Concert Pharmaceuticals Healthy Volunteers December 2010 Phase 1
NCT01388543 University of Colorado, Denver|National Institute of Allergy and Infectious Diseases (NIAID) HIV September 2006 Phase 4
NCT01105611 St. James's Hospital, Ireland HIV Infections|Hepatitis C August 2010 Phase 4
NCT00096850 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections|Tuberculosis
NCT01225705 University Hospital, Bonn|Dr. Axel Baumgarten, Berlin|Dr. Christoph Stephan, Frankfurt/M|Dr. Stefan Esser, Essen|Dr. Keikawus Arastéh, Berlin|Prof. Dr. Hans-Jürgen Stellbrink, Hamburg|Dr. Thomas Lutz, Frankfurt/M|Dr. Jörg Gölz , Berlin HIV|Hepatitis C October 2010 Phase 4
NCT02016924 Gilead Sciences Acquired Immune Deficiency Syndrome (AIDS)|HIV Infections January 16, 2014 Phase 2|Phase 3
NCT00756730 Daniel Skiest, MD|Tibotec Pharmaceutical Limited|Community Research Initiative of New England HIV Infections September 2008 Phase 4
NCT00718536 Germans Trias i Pujol Hospital HIV Infections August 2008 Phase 4
NCT00365339 Bristol-Myers Squibb HIV Infections April 2006 Phase 1
NCT00518297 Bristol-Myers Squibb|Merck Sharp & Dohme Corp. HIV Infections August 2007 Phase 1
NCT00006604 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group HIV Infections November 2000 Phase 1|Phase 2
NCT00896051 Janssen R&D Ireland HIV Infections|Acquired Immunodeficiency Syndrome August 2009 Phase 2
NCT01602822 Kenneth H. Mayer, MD|Bristol-Myers Squibb|Gilead Sciences|Abbott|Fenway Community Health HIV February 2012 Phase 4
NCT00273273 University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA) HIV Infections February 2006
NCT01108510 Gilead Sciences HIV|HIV Infections April 2010 Phase 3
NCT00892437 Gilead Sciences HIV-1 Infection May 2009 Phase 2
NCT00028301 Bristol-Myers Squibb HIV Infections February 2001 Phase 3
NCT01236235 Bristol-Myers Squibb|PharmaNet HIV January 2011
NCT01274780 Juan A. Arnaiz|Hospital Clinic of Barcelona HIV-1 May 2011 Phase 4
NCT00135395 Bristol-Myers Squibb HIV Infections May 2004 Phase 3
NCT00385645 Hospital Clinic of Barcelona HIV Infections May 2006 Phase 4
NCT00814879 Yale University|Bristol-Myers Squibb|Merck Sharp & Dohme Corp. Acquired Immune Deficiency Syndrome|AIDS|Human Immunodeficiency Virus|HIV Infections May 2009
NCT02246998 Gilead Sciences HIV-1 Infection December 2014 Phase 4
NCT01367236 Imperial College London|Pfizer HIV|Impaired Cognition January 2013 Phase 4
NCT00247845 University of British Columbia HIV Infections July 2004 Phase 4
NCT01106586 Gilead Sciences HIV|HIV Infections April 2010 Phase 3
NCT00491556 University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group HIV Infections October 2007
NCT02697851 St Stephens Aids Trust|Bristol-Myers Squibb HIV July 2016 Phase 1
NCT01159223 The HIV Netherlands Australia Thailand Research Collaboration|Kirby Institute|National Health Security Office, Thailand HIV Infections May 2011 Phase 4
NCT02603107 Gilead Sciences HIV-1 Infection November 20, 2015 Phase 3
NCT01967940 Gilead Sciences HIV|HIV Infections|Acquired Immunodeficiency Syndrome October 25, 2013 Phase 3
NCT01829802 Pedro Cahn|Merck Sharp & Dohme Corp.|The Huesped Foundation Chronic Infection With HIV May 2014 Phase 4
NCT01656109 The HIV Netherlands Australia Thailand Research Collaboration|amfAR, The Foundation for AIDS Research|National Health Security Office, Thailand|The Thai Government Pharmaceutical Organization (GPO) HIV July 2011 Phase 2
NCT00096746 Bristol-Myers Squibb HIV Infection November 2004
NCT01138267 The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|Kirby Institute|Radboud University|South East Asia Research Collaboration with Hawaii HIV Infections May 2009
NCT01910402 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus August 1, 2013 Phase 3
NCT02386098 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus July 8, 2015 Phase 2
NCT00335322 Kirby Institute|The University of New South Wales Human Immunodeficiency Virus (HIV) February 2007 Phase 4
NCT00118898 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections September 2005 Phase 3
NCT01605084 Bristol-Myers Squibb HIV June 2012 Phase 3
NCT01667978 University of Southern California|Society of Family Planning Pregnancy|HIV|AIDS June 2012
NCT01394133 University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infected July 2011
NCT00525239 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) HIV Infections March 2004
NCT02155101 University of Liverpool|Janssen Pharmaceutica|Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS|Yaounde Central Hospital HIV/AIDS May 2014 Phase 3
NCT01479361 National Institutes of Health Clinical Center (CC) HIV|PCP|Toxoplasmosis October 31, 2011 Phase 1
NCT00869960 University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) Healthy March 2009 Phase 4
NCT01803074 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus April 2013 Phase 2
NCT00540137 Imperial College London|Boehringer Ingelheim HIV Infections July 2007 Phase 4
NCT02652624 Gilead Sciences HIV-1 Infection February 1, 2016 Phase 3
NCT01445223 Göteborg University HIV April 2004 Phase 4
NCT01705574 Gilead Sciences Acquired Immunodeficiency Syndrome|HIV Infections October 24, 2012 Phase 3
NCT00007202 National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb HIV Infections Phase 2
NCT00551018 Merck Sharp & Dohme Corp. HIV Infections December 2007 Phase 2
NCT00532168 Juan A. Arnaiz|Hospital Clinic of Barcelona HIV Infections September 2007 Phase 4
NCT00811954 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Gilead Sciences|Merck Sharp & Dohme Corp.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV Infection May 2009 Phase 3
NCT00135447 Bristol-Myers Squibb HIV Infections September 2004
NCT00851799 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infection June 2009
NCT00122603 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|GlaxoSmithKline|Hoffmann-La Roche HIV Infections December 2005 Phase 2
NCT01456962 University of Colorado, Denver Women's Health|HIV Infection|Genital Diseases, Female October 2011
NCT02154360 University of Pennsylvania HIV Infection May 2014 Phase 1
NCT00820118 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infections May 2009 Phase 2
NCT02513147 Hospital Universitari Vall d'Hebron Research Institute|University Hospital, Ghent|IrsiCaixa HIV-1 June 2015 Phase 4
NCT00878306 University of California, San Francisco|National Institute on Drug Abuse (NIDA) HIV Infections|Drug Abuse November 2008 Phase 1
NCT01620944 Bristol-Myers Squibb HIV July 2012 Phase 3
NCT00624195 University of California, San Diego|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH) HIV Infections March 2007 Phase 2|Phase 3
NCT01459575 National Center for AIDS/STD Control and Prevention, China CDC|BMS company Antiretroviral Therapy July 2005
NCT01903031 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection November 2014 Phase 2
NCT00135434 Bristol-Myers Squibb HIV Infections September 2004 Phase 1
NCT01450618 Bristol-Myers Squibb HIV March 2011
NCT02641444 University of North Carolina, Chapel Hill HIV April 2016
NCT02404259 The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|Khon Kaen University HIV June 2010
NCT00867854 University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH) HIV-1|HIV Infections February 2009
NCT01565889 Gilead Sciences Hepatitis C|HIV March 2012 Phase 1|Phase 2
NCT00708162 Gilead Sciences HIV Infection July 2008 Phase 3
NCT02257008 Boehringer Ingelheim Healthy March 2003 Phase 1
NCT00977756 International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections August 2002
NCT00307502 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections January 2005 Phase 1
NCT01363011 Gilead Sciences Acquired Immunodeficiency Syndrome|HIV Infections May 2011 Phase 3
NCT01384734 Bristol-Myers Squibb Human Immunodeficiency Virus-1 July 2011 Phase 2
NCT02116660 Merck Sharp & Dohme Corp. HIV Infections September 3, 2014 Phase 2
NCT02397096 Merck Sharp & Dohme Corp. HIV-1 Infection June 9, 2015 Phase 3
NCT00666055 Kristine Patterson, MD|National Institute of Allergy and Infectious Diseases (NIAID)|University of North Carolina, Chapel Hill HIV Infections March 2008
NCT00042289 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections March 2003 Phase 4
NCT01805427 Hopital Lariboisière HIV Infection September 2012
NCT01417949 Universitätsklinikum Hamburg-Eppendorf HIV-Infection August 2011 Phase 4
NCT00884793 University of California, San Francisco HIV Infections September 2008
NCT02269917 Janssen R&D Ireland Human Immunodeficiency Virus Type 1 March 30, 2015 Phase 3
NCT00084136 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections May 2005 Phase 4
NCT00765154 St Stephens Aids Trust HIV October 2008 Phase 4
NCT00028314 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Lipodystrophy|Wasting Disease March 2002
NCT00877591 University of California, San Francisco|State University of New York at Buffalo|University of Utah Opioid Dependency|HIV Infections April 2008 Phase 1
NCT00421473 Radboud University HIV Infections|Malaria March 2007 Phase 4
NCT01289951 Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|Merck Sharp & Dohme Corp. Human Immunodeficiency Virus|Hepatitis C December 2010 Phase 1
NCT02227238 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus December 1, 2014 Phase 3
NCT01543035 Calmy Alexandra|Janssen-Cilag A.G., Switzerland|University Hospital, Geneva HIV Infection December 2011 Phase 3
NCT01908660 Valme University Hospital|Hospital Universitario Virgen de la Victoria|Hospital Universitario Reina Sofia|Hospital Torrecárdenas|Hospital de la Línea de la Concepción|Hospital Poniente|Hospital Universitario Virgen Macarena|Complejo Hospitalario de Especialidades Juan Ramón Jimenez Human Immunodeficiency Virus|Hepatitis B, Chronic|Hepatitis C, Chronic January 2007
NCT00013520 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 3
NCT00074581 National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network HIV Infections February 2005 Phase 3
NCT01467479 Vertex Pharmaceuticals Incorporated Hepatitis C December 2011 Phase 3
NCT00445146 Gilead Sciences HIV Infections February 2007 Phase 2
NCT01232361 International Maternal Pediatric Adolescent AIDS Clinical Trials Group ADHD|HIV September 2010
NCT01585753 Kirby Institute Cardiovascular Disease June 2012
NCT00665847 Tibotec Pharmaceuticals, Ireland HIV-1 November 2008 Phase 2
NCT01500616 Janssen-Cilag International NV Hepatitis C, Chronic June 2012 Phase 3
NCT01923311 Gilead Sciences Acquired Immune Deficiency Syndrome (AIDS)|HIV Infections August 26, 2013 Phase 2|Phase 3
NCT02302547 University Hospital, Tours|HOSPITAL, ORLEANS|Poitiers University Hospital|Centre Hospitalier de La Rochelle|HOSPITAL, SAINTES|HOSPITAL, FOCH|HOSPITAL, CAEN|HOSPITAL, HENRI MONDOR|HOSPITAL, HOTEL DIEU|HOSPITAL, CHARTRES|HOSPITAL, SAINT LOUIS|Tourcoing Hospital|HOSPITAL, NIORT|Tenon Hospital, Paris|Central Hospital, Nancy, France|University Hospital, Rouen HIV December 2014 Phase 3
NCT00966329 Germans Trias i Pujol Hospital HIV|HIV Infections October 2009 Phase 4
NCT02297126 Indiana University|National Human Genome Research Institute (NHGRI) Adverse Drug Reaction January 2015
NCT00260078 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections February 2006 Phase 1|Phase 2
NCT01814722 Merck Sharp & Dohme Corp. Human Immunodeficiency Virus November 9, 2012
NCT01815736 Gilead Sciences HIV|HIV Infections March 27, 2013 Phase 3
NCT01332955 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Janssen-Cilag Ltd. Hepatitis C, Chronic|HIV Infection April 2011 Phase 2
NCT02285114 Gilead Sciences HIV-1 January 2015 Phase 2|Phase 3
NCT00983853 Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited Hepatitis C|HIV Infections October 2009 Phase 2
NCT01637259 Kirby Institute Proteinuria|HIV June 2012 Phase 4
NCT01637233 Kirby Institute HIV-1 Infection June 2012
NCT01231685 McGill University Health Center|Merck Sharp & Dohme Corp.|CIHR Canadian HIV Trials Network HIV|Hepatitis C|Liver Fibrosis December 2011 Phase 2
NCT02605954 Gilead Sciences HIV-1 Infection November 18, 2015 Phase 3
NCT01475838 Gilead Sciences Acquired Immunodeficiency Syndrome|HIV Infections November 2011 Phase 3
NCT01252940 Gilead Sciences HIV-1 Infection November 2010 Phase 3
NCT02157311 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV-1 Infection July 2014 Phase 3
NCT02457494 Corinne Isnard Bagnis|Association pour le Developpement d'Investigations et de Thérapeutiques en Néphrologie Nephrolithiasis|HIV May 2015
NCT01939197 AbbVie Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics August 2013 Phase 3
NCT02121795 Gilead Sciences HIV-1 Infection May 8, 2014 Phase 3
NCT02469246 Gilead Sciences HIV-1 Infection June 29, 2015 Phase 3
NCT02951052 ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline Infection, Human Immunodeficiency Virus October 28, 2016 Phase 3
NCT02556268 Bayer HIV-DDI February 2016 Phase 1
NCT01335529 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Rennes University Hospital|Merck Sharp & Dohme Corp. HCV Coinfection|HIV-1 Infection May 2011 Phase 2
NCT02616783 Gilead Sciences HIV-1 Infection December 22, 2015 Phase 3
View MoreCollapse
References
M.Wt

704.86

Formula

C₃₈H₅₂N₆O₇

CAS No.

198904-31-3

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Atazanavir
Cat. No.:
HY-17367
Quantity: